Skip to content

Author

Ji-Sheng Li

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Nov 2026

Expert consensus on the diagnosis and treatment of EGFR gene mutation non-small cell lung cancer

Abstract Background: Epidermal growth factor receptor (EGFR) mutations are the most clinically actionable oncogenic drivers in Asian patients with non-small-cell lung cancer (NSCLC). The therapeutic landscape has rapidly evolved from single-agent EGFR tyrosine kinase inhibitors (TKIs) to risk-adapted first-line intensi...

R. Meng, Chun-Wei Xu, Wen-Xian Wang et al. · 0 citations
Open access Sep 2026

Cost-effectiveness of durvalumab consolidation therapy in limited-stage small-cell lung cancer: A Chinese and U.S. payer perspective analysis.

BACKGROUND The ADRIATIC trial has established durvalumab as a new standard of care for limited-stage small-cell lung cancer (LS-SCLC) by showing significant survival benefits after chemoradiotherapy (CRT). In this study, the cost-effectiveness of this regimen was evaluated from Chinese and U.S. payer perspectives. ME...

Cheng-Jun Wang, Shi-Xian Liu, Chuang Yang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.